GlaxoSmithKline Pharmaceuticals' Q2 FY26 profit grows despite revenue dip

GlaxoSmithKline Pharmaceuticals Limited reported Q2 FY26 standalone financial highlights, with revenue at ₹974cr, a 2.6% decrease year-on-year. This was attributed to supply constraints, GST changes, and external competitive market share performance. Despite the revenue dip, EBITDA grew 4.9% year-on-year to ₹335cr, with the EBITDA margin improving by 250 basis points to 34.4%. This improvement was driven by gross margin gains and operating leverage, supported by maintained field productivity.

The company's profit after tax (PAT) for Q2 FY26 stood at ₹253cr, marking a 3.3% growth year-on-year, with the PAT margin increasing by 150 basis points to 26.1%. This profitability improvement was a result of consistent gross margin improvement and cost management. Earnings per share (EPS) for the quarter were ₹15.06, up 3%.

Strategic initiatives included the specialty segment driving growth with oncology product launches, a 13% growth in the Paediatric Vaccines portfolio led by brands like Boostrix and Varilrix, and strong Shingrix performance through HCP and HCO partnerships. Key brands continued to outperform in their respective markets, gaining share and maintaining leadership.